

ASX ANNOUNCEMENT

23 August 2021

Media Interest Surrounding MIPS' mRNA Receptor Binding Protein Vaccine Candidate and IDT Finalises Sterile Readiness Agreement With The Australian Government

- *Recent media interest over the weekend surrounding mRNA receptor binding protein vaccine candidate developed by Monash Institute of Pharmaceutical Sciences with the support of the Victorian Government.*
- *Sterile Readiness Agreement finalised between IDT and The Department of Health (Health) to bring IDT's sterile manufacturing facility into a state of readiness to potentially produce a COVID-19 vaccine.*
- *The Sterile Readiness Agreement provides for an exclusivity period with the Australian Government for the use of IDT's sterile manufacturing facility until the earlier of: executing a Supply Agreement for IDT to provide COVID-19 vaccine services to Health, or 4 months from completion of IDT's sterile readiness works.*
- *IDT's sterile readiness activities are being undertaken on a "vaccine agnostic" basis, meaning that IDT will be readying the facility to potentially manufacture a COVID-19 vaccine which may be nominated by the Government at its discretion during the exclusivity period.*

IDT Australia Limited (ASX: IDT) provides the following market updates.

Further to the Company's announcement on 22 June 2021 there has been strong media interest over the weekend regarding IDT's ongoing discussions with the Victorian Government and Monash Institute of Pharmaceutical Sciences (MIPS) with respect to IDT potentially providing cGMP manufacturing services for the

production of MIPS' receptor binding domain mRNA COVID-19 vaccine candidate. IDT confirms that these discussions have recently extended to include the Commonwealth Government, the Victorian State Government and Monash University and are progressing well.

On 19 March 2021 the Company announced that the Australian Government (Government), Department of Health had requested IDT to commence a feasibility assessment covering sterile facility recommissioning and sterile readiness activities. The purpose of these activities was to assess and ready IDT's sterile manufacturing facility to potentially provide additional local production capability for a COVID-19 vaccine. The Department of Health and IDT have today finalised a Sterile Readiness Agreement to formalise these activities.

The **Key Terms** of the Sterile Readiness Agreement are as follows:

Scope: This agreement formalises the discussions between Health and IDT in regards to recommissioning activities to bring IDT's Melbourne based sterile manufacturing facilities into a state of sterile readiness so that IDT can use those facilities to provide assistance to Health in connection with Health's rollout of COVID-19 vaccines in Australia.

Exclusivity: IDT agrees to ensure the production capacity of its sterile facility will be retained exclusively for Health or Health's nominee until the earlier of: executing a Supply Agreement to deliver a COVID-19 vaccine, or 4 months from completion of IDT's sterile readiness works.

IDT expects that the remaining activities relating to the sterile facility recommissioning and sterile readiness works will continue for the next 1-2 months. At the conclusion of these activities IDT will maintain the facility in a sterile state, exclusively for the Government. During the exclusivity period the Government in its discretion can nominate a COVID-19 vaccine - in which case IDT and the relevant vaccine company would need to agree on commercial terms for the manufacture of the specific COVID-19 vaccine.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Health has been briefed on IDT potentially providing cGMP manufacturing support for Australia's first locally developed COVID-19 mRNA vaccine candidate, developed by Monash/Monash Institute of Pharmaceutical Sciences with the support of the Victorian Government.

"IDT has now formalised its activities with the Australian Government to be ready to potentially assist with the production of a COVID-19 vaccine." said IDT's CEO Dr David Sparling. "As we have seen in recent weeks, the environment surrounding COVID-19 is very dynamic. IDT is doing what it can to be ready and is standing-by for direction from Government."

The Company will provide updates as additional information comes to hand.

Ends.../

IDT

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

Dr David Sparling

Chief Executive Officer - IDT Australia Limited

+61 3 9801 8888

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.